Friday 6-20-2014 Biomarin Pharmaceutical Inc (BMRN) $BMRN opened at 62.74 hitting the high price of 67.11 and a day low of 62.61 with a total volume of 3,098,694. BMRN had a previous close of 62.41 and has been seeing an average volume of 1,519,585.
Overall Average: 56% Buy
Recent stock forum discussions about BMRN http://investorshangout.com/search?q=BMRN&...mp;yt0=Go!
Watch for BioMarin Pharmaceutical to Potentially Pullback After Gaining 5.90% Yesterday
Comtex SmarTrend(R) - Fri Jun 20, 4:24PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $62.61 to a high of $67.11. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $63.50 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate
at The Street - Fri Jun 20, 1:19PM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate (full story)
Relypsa Adds Industry Veterans Daniel K. Spiegelman and kenneth J. Hillan to Its Board of Directors
GlobeNewswire - Thu Jun 19, 3:05PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the election of Daniel K. Spiegelman, executive vice president and chief financial officer of BioMarin Pharmaceutical Inc., and Kenneth J. Hillan, president and chief executive officer of Achaogen, Inc., to its board of directors following the company's annual meeting of stockholders held earlier today. Mr. Spiegelman and Dr. Hillan are well established biopharmaceutical executives with expertise in managing public companies through research and development to international commercial operations. (full story)
How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today?
at The Street - Thu Jun 12, 6:53AM CDT
BioMarin Pharmaceutical (BMRN) is rated a 'buy' this morning at UBS (UBS) with a $74 price target as the firm said it's an 'attractive entry point for a mid-cap holding." (full story)
Mantle Cell Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6jdmb/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - ImmunoGen, Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Teva Pharmaceutical Industries Limited - Cell Therapeutics, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/p6...antle_cell (full story)
BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th
GlobeNewswire - Tue Jun 10, 7:00AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that management will present at the Wells Fargo Healthcare Conference in Boston on Tuesday, June 17 at 9:25am ET. (full story)
Upgrade Alert for BioMarin Pharmaceutical (BMRN)
Comtex SmarTrend(R) - Mon Jun 09, 7:15AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $61.74 on volume of 3.7 million shares, above average daily volume of 1.5 million. In the past 52 weeks, BioMarin Pharmaceutical share prices have been bracketed by a low of $53.53 and a high of $84.25 and closed yesterday at $61.74, 15% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2% while the 200-day MA has remained constant. (full story)
How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today?
at The Street - Mon Jun 09, 6:54AM CDT
Shares of Biomarin Pharmaceutical (BMRN) were upgraded to 'outperform' from 'neutral' at Credit Suisse (CS) which maintained its $73 price target. (full story)
Global Phenylketonuria (PKU) Clinical Trials Report 2014
M2 - Fri Jun 06, 4:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnxg8w/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" report to their offering. Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" provides data on the Phenylketonuria (PKU) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Phenylketonuria (PKU). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Phenylketonuria (PKU). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - BioMarin Pharmaceutical Inc. - E. Merck KG - Emory University - University of Leipzig - Washington University School of Medicine - University of Miami - University of Southern California - Ludwig-Maximilians-Universitat Munich - The University of Texas Health Science Center at Houston - Hamilton Health Sciences - University Hospital, Tours - University of Missouri For more information visit http://www.researchandmarkets.com/research/jn...lketonuria (full story)
Global Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Clinical Trials Report 2014
M2 - Fri Jun 06, 4:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bnrww/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014" report to their offering. Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014 includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Shire Plc - UniQure NV - Lysogene - Synageva BioPharma Corp. - Cytomedix, Inc. - BioMarin Pharmaceutical Inc. - Academic Medical Center - Masonic Cancer Center - The University of Manchester - The University of Chicago - Hospices Civils de Lyon - University of Louisville - University of Minnesota For more information visit http://www.researchandmarkets.com/research/2b...saccharido (full story)
Shares of BMRN Down 19.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 04, 9:55AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 3 months, BioMarin Pharmaceutical has returned 19.08% as of today's recent price of $61.26. (full story)
Insider Trading Alert - TWO, CCL And BMRN Traded By Insiders
at The Street - Wed Jun 04, 9:30AM CDT
Stocks with insider trader activity include TWO, CCL and BMRN (full story)
Watch for BioMarin Pharmaceutical to Potentially Pullback After Gaining 6.17% Yesterday
Comtex SmarTrend(R) - Tue Jun 03, 4:33PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $57.26 to a high of $62.03. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $58.46 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Life After Pfizer: AstraZeneca Hopes for Oncology Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 03, 8:00AM CDT
European and U.S. regulators this year are considering approval for AstraZeneca 's Olaparib, a drug designed to treat ovarian cancer patients with a specific mutation to the BRCA gene. Approval could have an impact on a variety of other... (full story)
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma
PR Newswire - Fri May 30, 7:30AM CDT
On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones Industrial Average advanced 0.39%, to finish the day at 16,698.74, and the S&P 500 closed at 1,920.03, up 0.54%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.45, up 0.76%, with the index advancing 2.45% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Amgen Inc. (NASDAQ: AMGN) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on BMRN, KERX, AMGN and PPHM can be downloaded upon signing up at: (full story)
BioMarin's Pipeline Advances - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 10:40AM CDT
BioMarin dosed the first patient in a study on BMN 701. (full story)
24.2% Return Seen to Date on SmarTrend BioMarin Pharmaceutical Call (BMRN)
Comtex SmarTrend(R) - Wed May 28, 9:14AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 3 months, BioMarin Pharmaceutical has returned 24.17% as of today's recent price of $57.40. (full story)
After Yesterday's Rally of 1.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 27, 5:56PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $56.24 to a high of $57.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $57.31 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease
GlobeNewswire - Tue May 27, 7:01AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA) in the Phase 3 INSPIRE trial for Pompe disease. BMN 701 is a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), designed to target delivery to the lysosomes where the enzyme is most needed. The INSPIRE trial focuses on late onset Pompe disease - an inherited condition caused by a deficiency in the lysosomal enzyme acid alpha glucosidase, which can lead to progressive weakening of the muscles of the body, including the diaphragm, a crucial respiratory muscle. Respiratory impairment is the leading cause of morbidity and mortality in late onset Pompe disease. (full story)
Downtrend Call Working As BioMarin Pharmaceutical Stock Falls 25.8% (BMRN)
Comtex SmarTrend(R) - Tue May 20, 5:01PM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 2 months, BioMarin Pharmaceutical has returned 25.83% as of today's recent price of $56.15. (full story)
Overall Average: 56% Buy
Recent stock forum discussions about BMRN http://investorshangout.com/search?q=BMRN&...mp;yt0=Go!
Watch for BioMarin Pharmaceutical to Potentially Pullback After Gaining 5.90% Yesterday
Comtex SmarTrend(R) - Fri Jun 20, 4:24PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $62.61 to a high of $67.11. Yesterday, the shares gained 5.9%, which took the trading range above the 3-day high of $63.50 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate
at The Street - Fri Jun 20, 1:19PM CDT
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate (full story)
Relypsa Adds Industry Veterans Daniel K. Spiegelman and kenneth J. Hillan to Its Board of Directors
GlobeNewswire - Thu Jun 19, 3:05PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the election of Daniel K. Spiegelman, executive vice president and chief financial officer of BioMarin Pharmaceutical Inc., and Kenneth J. Hillan, president and chief executive officer of Achaogen, Inc., to its board of directors following the company's annual meeting of stockholders held earlier today. Mr. Spiegelman and Dr. Hillan are well established biopharmaceutical executives with expertise in managing public companies through research and development to international commercial operations. (full story)
How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today?
at The Street - Thu Jun 12, 6:53AM CDT
BioMarin Pharmaceutical (BMRN) is rated a 'buy' this morning at UBS (UBS) with a $74 price target as the firm said it's an 'attractive entry point for a mid-cap holding." (full story)
Mantle Cell Lymphoma - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6jdmb/mantle_cell) has announced the addition of the "Mantle Cell Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mantle Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mantle Cell Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mantle Cell Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Gilead Sciences, Inc. - Merck & Co., Inc. - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - ImmunoGen, Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Teva Pharmaceutical Industries Limited - Cell Therapeutics, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/p6...antle_cell (full story)
BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th
GlobeNewswire - Tue Jun 10, 7:00AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today announced that management will present at the Wells Fargo Healthcare Conference in Boston on Tuesday, June 17 at 9:25am ET. (full story)
Upgrade Alert for BioMarin Pharmaceutical (BMRN)
Comtex SmarTrend(R) - Mon Jun 09, 7:15AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $61.74 on volume of 3.7 million shares, above average daily volume of 1.5 million. In the past 52 weeks, BioMarin Pharmaceutical share prices have been bracketed by a low of $53.53 and a high of $84.25 and closed yesterday at $61.74, 15% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2% while the 200-day MA has remained constant. (full story)
How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today?
at The Street - Mon Jun 09, 6:54AM CDT
Shares of Biomarin Pharmaceutical (BMRN) were upgraded to 'outperform' from 'neutral' at Credit Suisse (CS) which maintained its $73 price target. (full story)
Global Phenylketonuria (PKU) Clinical Trials Report 2014
M2 - Fri Jun 06, 4:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jnxg8w/phenylketonuria) has announced the addition of the "Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" report to their offering. Phenylketonuria (PKU) Global Clinical Trials Review, H1, 2014" provides data on the Phenylketonuria (PKU) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Phenylketonuria (PKU). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Phenylketonuria (PKU). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - BioMarin Pharmaceutical Inc. - E. Merck KG - Emory University - University of Leipzig - Washington University School of Medicine - University of Miami - University of Southern California - Ludwig-Maximilians-Universitat Munich - The University of Texas Health Science Center at Houston - Hamilton Health Sciences - University Hospital, Tours - University of Missouri For more information visit http://www.researchandmarkets.com/research/jn...lketonuria (full story)
Global Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Clinical Trials Report 2014
M2 - Fri Jun 06, 4:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2bnrww/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014" report to their offering. Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Global Clinical Trials Review, H1, 2014 includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Shire Plc - UniQure NV - Lysogene - Synageva BioPharma Corp. - Cytomedix, Inc. - BioMarin Pharmaceutical Inc. - Academic Medical Center - Masonic Cancer Center - The University of Manchester - The University of Chicago - Hospices Civils de Lyon - University of Louisville - University of Minnesota For more information visit http://www.researchandmarkets.com/research/2b...saccharido (full story)
Shares of BMRN Down 19.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Jun 04, 9:55AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 3 months, BioMarin Pharmaceutical has returned 19.08% as of today's recent price of $61.26. (full story)
Insider Trading Alert - TWO, CCL And BMRN Traded By Insiders
at The Street - Wed Jun 04, 9:30AM CDT
Stocks with insider trader activity include TWO, CCL and BMRN (full story)
Watch for BioMarin Pharmaceutical to Potentially Pullback After Gaining 6.17% Yesterday
Comtex SmarTrend(R) - Tue Jun 03, 4:33PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $57.26 to a high of $62.03. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $58.46 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
Life After Pfizer: AstraZeneca Hopes for Oncology Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Jun 03, 8:00AM CDT
European and U.S. regulators this year are considering approval for AstraZeneca 's Olaparib, a drug designed to treat ovarian cancer patients with a specific mutation to the BRCA gene. Approval could have an impact on a variety of other... (full story)
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma
PR Newswire - Fri May 30, 7:30AM CDT
On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones Industrial Average advanced 0.39%, to finish the day at 16,698.74, and the S&P 500 closed at 1,920.03, up 0.54%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index ended the day at 688.45, up 0.76%, with the index advancing 2.45% in the last one month. Investor-Edge has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Amgen Inc. (NASDAQ: AMGN) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on BMRN, KERX, AMGN and PPHM can be downloaded upon signing up at: (full story)
BioMarin's Pipeline Advances - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 29, 10:40AM CDT
BioMarin dosed the first patient in a study on BMN 701. (full story)
24.2% Return Seen to Date on SmarTrend BioMarin Pharmaceutical Call (BMRN)
Comtex SmarTrend(R) - Wed May 28, 9:14AM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 3 months, BioMarin Pharmaceutical has returned 24.17% as of today's recent price of $57.40. (full story)
After Yesterday's Rally of 1.13% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 27, 5:56PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $56.24 to a high of $57.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $57.31 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease
GlobeNewswire - Tue May 27, 7:01AM CDT
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA) in the Phase 3 INSPIRE trial for Pompe disease. BMN 701 is a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), designed to target delivery to the lysosomes where the enzyme is most needed. The INSPIRE trial focuses on late onset Pompe disease - an inherited condition caused by a deficiency in the lysosomal enzyme acid alpha glucosidase, which can lead to progressive weakening of the muscles of the body, including the diaphragm, a crucial respiratory muscle. Respiratory impairment is the leading cause of morbidity and mortality in late onset Pompe disease. (full story)
Downtrend Call Working As BioMarin Pharmaceutical Stock Falls 25.8% (BMRN)
Comtex SmarTrend(R) - Tue May 20, 5:01PM CDT
SmarTrend identified a Downtrend for BioMarin Pharmaceutical (NASDAQ:BMRN) on March 7th, 2014 at $75.70. In approximately 2 months, BioMarin Pharmaceutical has returned 25.83% as of today's recent price of $56.15. (full story)
